Tag: mantle cell lymphoma first-line therapy

Home / mantle cell lymphoma first-line therapy

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
mantle-cell-lymphoma-first-line-therapy

Scan the code